Italia markets closed

Eisai Co., Ltd. (4523.T)

Tokyo - Tokyo Prezzo differito. Valuta in JPY.
Aggiungi a watchlist
6.256,00-154,00 (-2,40%)
Alla chiusura: 03:15PM JST

Eisai Co., Ltd.

4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3700
https://www.eisai.co.jp

Settore/iHealthcare
SettoreDrug Manufacturers - Specialty & Generic
Impiegati a tempo pieno

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Haruo NaitoCEO, Representative Corporate Officer & DirectorN/DN/D1947
Mr. Gary HendlerSenior VP & President of EMEA RegionN/DN/D1966
Dr. Lynn D. Kramer FAAN, M.D.Vice President & Chief Clinical Officer - Alzheimer's Disease and Brain HealthN/DN/D1950
Ms. Yanhui FengSenior Vice PresidentN/DN/D1972
Dr. Nadeem Sarwar Ph.D.PresidentN/DN/DN/D
Mitsuru ShomonVP & CFON/DN/DN/D
Mr. Yasushi OkadaRepresentative Corporate Officer, COO, Industry Affairs, China Business & Data IntegrityN/DN/D1958
Makoto HoketsuVP & Chief Information OfficerN/DN/DN/D
Mr. Masatomi AkanaChief Gov. Rel. and IR Officer, SVP of Global Value, Acc., Japan Subs, General, Env. & Safety Aff.N/DN/D1967
Mr. Kenta TakahashiExecutive VP of IP, Internal Audit & Control, General Counsel and Chief Compliance OfficerN/DN/D1959
Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in JPY.

Descrizione

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Governance aziendale

L'ISS Governance QualityScore di Eisai Co., Ltd. al 1 giugno 2024 è 1. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 1; diritti degli azionisti: 7; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.